Introduction {#Sec1}
============

Prostate cancer is the third-leading cause of cancer death in men in the USA, with an estimated 29,430 deaths in 2018 \[[@CR1]\]. Androgen receptor signaling is a dependent-molecular mechanism behind prostate cancer progression, and thus androgen deprivation therapy (ADT) is administered to men with advanced prostate cancer \[[@CR2]\]. Surgical ADT, or bilateral orchiectomy, involves removal of the testes and spermatic cord \[[@CR3]\] resulting in a more permanent testosterone depletion. Medical or chemical ADT involves chronic administration of luteinizing hormone-releasing hormone (LHRH) agonists or antagonists like Cerorelix, Ganirelix, Abarelix, or Degarelix \[[@CR4]\]. During the first 1--3 weeks of LHRH-agonist therapy, the therapies may cause a temporary increase in testosterone, commonly referred to as a "flare" \[[@CR5], [@CR6]\]. Symptoms of a flare may include bone pain, uremia, ureteral obstruction, and development of neurologic sequelae, and the increase in testosterone may lead to a rapid progression of disease \[[@CR7]\]. The use of medical or surgical ADT in conjunction with a non-steroidal anti-androgen is referred to as "combined androgen blockade" (CAB) and attempts to block androgens from all sources \[[@CR6], [@CR8]\]. The use of CAB compared with ADT alone has been controversial, with some meta-analyses of clinical trials reporting improvement in overall survival in patients treated with CAB and others reporting inconclusive results with high frequency of adverse health effects in CAB-treated patients \[[@CR8], [@CR9]\]. A 2007 RCT study by Akaza et al. showed that bicalutamide 80 mg offered a significant overall survival benefit compared with LHRH-agonist monotherapy without reducing tolerability in patients with locally advanced or metastatic prostate cancer \[[@CR10]\].

Bicalutamide (BIC) is a non-steroidal, first-generation anti-androgen FDA-indicated for use in combination therapy with a LHRH analog approved for the treatment of Stage D2 metastatic carcinoma of the prostate. BIC blocks the effects of adrenal androgens at the androgen receptor to potentially prevent testosterone flare. A recent meta-analysis of both randomized clinical trials and observational studies demonstrated a non-statistically significant improvement in rates of disease flare among men taking an androgen suppressant and an anti-androgen compared with androgen suppression alone \[[@CR7], [@CR11]\]. Additionally, during and before this study period, no prospective randomized control trials have demonstrated a survival advantage with CAB over the serial use of a LHRH agonist and an anti-androgen \[[@CR12]\]. Therefore, it is important to understand the treatment patterns and characteristics of BIC use within the prostate cancer population. The objectives of this research were to identify a cohort of BIC-treated elderly patients with prostate cancer, characterize them with respect to their disease severity, age, race, and presence of comorbidities, and describe the patterns of BIC use in relation to ADT.

Methods {#Sec2}
=======

Data Sources {#Sec3}
------------

The SEER-Medicare database links cancer registry information in selected US geographic areas with claims for covered health care services of Medicare beneficiaries. The SEER program represents approximately 28% of the US population, whereas Medicare covers health services for 97% of people aged 65 years and older. About 55% of SEER patients are ≥ age 65 and approximately 94% have been successfully linked with their Medicare claims \[[@CR13]--[@CR15]\]. Geographic areas selected for inclusion in SEER are based on adherence to operating and maintaining a high-quality, population-based cancer reporting system and specific patient populations of interest \[[@CR16]\]. The SEER-Medicare database analytic variables include patient demographics at diagnosis (e.g., age and gender), tumor characteristics, Medicare enrollment information, International Classification of Diseases, Ninth Revision, Clinical Modification diagnoses and procedure codes, Healthcare Common Procedure Coding System and Current Procedural Terminology codes, and prescription claims data.

Study Design and Population {#Sec4}
---------------------------

Incident prostate cancer cases diagnosed between January 1, 2007 and December 31, 2011 followed until December 31, 2013, with claims data reporting at least one filled BIC prescription any point after diagnosis were included in the study cohort (Fig. [1](#Fig1){ref-type="fig"}). All patients were required to be enrolled in Medicare parts A and B for the 12 months prior to their diagnosis and at least 2 years after diagnosis (or until death or the end of study observation). These restrictions ensured that a modified Charlson comorbidity scores could be calculated to capture comorbidity at diagnosis \[[@CR17], [@CR18]\] and that complete claims information would be available. Likewise, patients who were members of a Health Maintenance Organization were also excluded based upon same rational. Additional inclusion and exclusion information is detailed in Fig. [1](#Fig1){ref-type="fig"}. The Wayne State University Institutional Review Board determined that the study was Non-Human Participant Research (HPR\# 2015-48). Thus, this article does not contain any studies with human participants or animals performed by any of the authors.Fig. 1Patient flow diagram

Statistical Analysis {#Sec5}
--------------------

The distribution of patient demographic and clinical characteristics is presented in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}, respectively. Prostate cancer treatments administered as first- and second-line therapies were described as ADT use, including both surgical and chemical ADT, where surgical ADT was defined as bilateral orchiectomy, and chemical ADT was defined as the administration of Leuprolide Acetate, Goserelin Acetate, Triptorelin, Histrelin (LHRH agonists), or Degarelix (LHRH antagonist). As no formal time frame for CAB treatment has been established \[[@CR19]\], in this study, CAB was defined as BIC use within 6 months of ADT based on clinical recommendation. A sensitivity analysis was performed using a 4-month window for CAB. Treatment patterns for BIC use in relation to ADT administration were divided into 4 categories: (1) BIC use alone as monotherapy (without ADT), (2) BIC as part of CAB (with ADT), (3) BIC as part of CAB followed by monotherapy, and (4) other (BIC use begun \> 6 months before orchiectomy or chemical ADT and continued into CAB period).Table 1Demographic and clinical characteristics at diagnosis and treatment for prostate cancer patients that filled a prescription for bicalutamide any time after diagnosis*n*%Total7521Age group (years) 65--69147219.6 70--74213628.4 75--79181524.1 80--84131417.5 85 +78410.4Race/ethnicity Non-hispanic white532070.7 Non-hispanic black6418.5 Hispanic78410.4 Non-hispanic Asian4015.3 Other/unknown3755.0SEER region Midwest104413.9 Northeast151020.1 South129417.2 West367348.8Year of diagnosis 2007183824.4 2008150520.0 2009144319.2 2010137418.3 2011136118.1Rural status Big metro/metro611281.3 Urban/less urban122116.2 Rural1882.5Census tract poverty 0 to \< 5% poverty184724.6 5 to \< 10% poverty202026.9 10 to \< 20% poverty203927.1 20--100% poverty154720.6 Unknown680.9Marital status Single (never married)6318.4 Married (or equivalent)448459.6 Separated390.5 Divorced3855.1 Widowed6939.2 Unknown128917.1Vital status Alive552873.5 Death due to prostate cancer97713.0 Death due to other cause101613.5Months of follow-up Mean (SD)56.1 (0.2) Median (range)57 (0--83)AJCC stage I--II481064.0 III4776.3 IV139918.6 Unknown or NA83511.1SEER stage Local513168.2 Regional81610.9 Distant1,11514.8 Unknown4596.1Gleason grade 6103713.8 7241432.1 8140918.7 9149619.9 102353.1 Unknown93012.4Metastases at diagnosis M0572876.2 M1NOS380.5 M1a610.8 M1b76410.2 M1c2423.2MX6889.2Charlson comorbidity index^a^ 0339845.2 1198426.4 2104113.8 3 +109814.6Primary treatment^a^ Radical prostatectomy4385.8 Radiation6999.3 ADT: surgical871.2 ADT: chemical562574.8 Chemotherapy2683.6 Abiraterone acetate\< 11 Enzalutamide\< 11 Flutamide520.7 Sipuleucel-T\< 11 Radium 223 dichloride\< 11 BIC only and other3384.5Second-line treatment^b^ Radical prostatectomy1291.7 Radiation210928.0 ADT: surgical360.5 ADT: chemical88611.8 Chemotherapy7349.8 Abiraterone acetate801.1 Enzalutamide\< 11 Flutamide831.1 Sipuleucel-T300.4 Radium 223 dichloride\< 11 None or other342345.5*ADT* androgen deprivation therapy, *NA* not applicable, *NOS* not otherwise specified^a^Calculated using the standard SEER-Medicare macro which is a modified version that excludes cancer diagnoses^b^Primary treatment defined by the first treatment date after diagnosis; secondary treatment defined by the first date of a new treatment type Table 2Definitions of BIC patterns in relation to androgen deprivation therapyCategoryDefinitionBIC monotherapyBIC prescription without any ADT\
First and last BIC prescription more than 6 months before orchiectomy\
Last BIC prescription (plus days supply) more than 6 months before the start of chemical ADT\
First BIC prescription more than 6 months after the end of chemical ADTCABFirst BIC prescription within 6 months before orchiectomy\
First BIC prescription after orchiectomy\
First BIC prescription within 6 months of chemical ADT start and last BIC prescription (plus days supply) before 6 months after chemical ADT end\
First BIC prescription after chemical ADT start and last BIC prescription (plus days supply) before 6 months after chemical ADT endCAB followed by monotherapyFirst BIC prescription within 6 months of chemical ADT start and last BIC prescription (plus days supply) more than 6 months after the end of chemical ADT\
First BIC prescription after ADT start and before last BIC prescription (plus days supply filled) plus 6 months; last BIC prescription more than 6 months after the end of chemical ADTOtherFirst and BIC prescription more than 6 months before orchiectomy and continued into CAB period\
First BIC prescription more than 6 months before the start of chemical ADT and continued into CAB periodAdditional CAB variables BIC only within 2 months of LHRH agonist startFirst BIC prescription within 2 months of LHRH agonist start and last BIC prescription (plus days supply) within 2 months of LHRH agonist start All other BIC and CAB useCAB with first BIC prescription more than 2 months before LHRH agonist start\
CAB with first BIC prescription more than 2 months after LHRH agonist start\
CAB with first BIC prescription within 2 months of LHRH agonist start and last BIC prescription (plus days supply) more than 2 months of LHRH agonist start\
CAB with BIC use within 6 months of orchiectomy or after orchiectomy\
CAB with BIC use within 6 months of LHRH antagonist start and/or stop\
CAB with a combination of BIC use and LHRH agonist and/or LHRH antagonist and/or orchiectomy within 6 months of ADT start and/or stop*ADT* androgen deprivation therapy, *BIC* bicalutamide, *CAB* complete androgen blockade, *LHRH* luteinizing hormone-releasing hormone analog

Current National Comprehensive Cancer Network guidelines recommend that BIC precede or be co-administered with LHRH agonists for at least 7 days for testosterone flare prevention \[[@CR19]\] for men with metastatic disease. In this study, the treatment for potential testosterone flare is defined as ≥ 1 prescription for BIC within 2 months before or after LHRH agonist therapy initiation. The 2-month window identifies patients who may have filled their prescriptions up to 35 days before LHRH agonist treatment initiation, but not initiated until 30 days prior \[[@CR20]--[@CR27]\]. To evaluate potential BIC used for testosterone flare only, the CAB category was stratified into BIC use only within ± 2 months of LHRH agonist start. These time periods are displayed in Fig. [2](#Fig2){ref-type="fig"}. The BIC treatment duration was calculated in terms of months from the first BIC claim to the last BIC claim, plus the number of days' supply. The distribution of BIC and ADT use patterns were described overall and stratified by metastatic disease at diagnosis (M0 versus M1). In addition, the median, mode, and range of months of BIC use were calculated by treatment category. All analyses were completed using SAS v.9.4 (SAS Institute, Cary, NC, USA).Fig. 2Bicalutamide treatment in relation to androgen deprivation therapy

Results {#Sec6}
=======

Patient Characteristics {#Sec7}
-----------------------

The majority of patients included in this study were non-Hispanic white (71%) and lived in a metropolitan area (81%) (Table [1](#Tab1){ref-type="table"}). At the end of the study follow-up period (December 31, 2013), 13% of the cohort had died of prostate cancer and 14% had died from other causes (Table [1](#Tab1){ref-type="table"}).

Most men (64%) had AJCC stage I--II cancer at diagnosis and 76% had no metastases at diagnosis. The Charlson Comorbidity Index score was 0--1 for 72% of participants. Chemical ADT was administered as primary treatment for nearly three-quarters of the cohort. Radiation was the primary second-line treatment used in 28% of the cohort, followed by chemical ADT, which was used by 12% of the cohort (Table [1](#Tab1){ref-type="table"}).

Treatment Patterns and Duration {#Sec8}
-------------------------------

Table [2](#Tab2){ref-type="table"} includes the definitions used to classify BIC treatment pattern categories in relation to ADT as defined by BIC and ADT start and stop dates, as illustrated in Fig. [2](#Fig2){ref-type="fig"}. Eighteen percent of the cohort used BIC as monotherapy, with over half of patients (54%) using BIC as part of CAB and 27% using BIC as part of CAB followed by monotherapy. Among men treated with BIC as part of CAB, 58% (*n* = 2327) used BIC only within 2 months of LHRH agonist start, which may indicate use for testosterone flare only. A small number of patients (*n* = 122) began BIC treatment more than 6 months before bilateral orchiectomy or chemical ADT start and continued on therapy within the study's CAB window. These patients had the longest median BIC treatment duration (29.7 months), followed by the patients treated with BIC as part of CAB followed by monotherapy (median 21.0 months of BIC therapy). Patients receiving BIC monotherapy persisted for a median of 4.4 months, while the majority of all BIC patients had only a median of 1 month of therapy with CAB.

Compared to men without metastatic prostate disease at diagnosis, more men diagnosed with metastatic prostate cancer used BIC as part of CAB followed by monotherapy (42 vs. 24%) and fewer used BIC as part of CAB (41 vs. 56%). Among metastatic patients who used BIC as part of CAB, only 35% used BIC within 2 months of LHRH agonist start, indicating a smaller proportion of metastatic prostate cancer patients using BIC during the 'flare' period than patients without metastatic disease at diagnosis (61%). Additional details about duration of BIC use can be found in Table [3](#Tab3){ref-type="table"}.Table 3Patterns of bicalutamide use with androgen deprivation therapy\**n*%Duration of BIC Treatment (months)^a^MedianModeRangeAll cases BIC monotherapy134817.94.41.00.2--83.3 Complete androgen blockade402553.51.01.00.1--84.5  BIC only within ± 2 months of LHRH agonist start23271.01.00.1--3.8  All other BIC and CAB use16984.93.00.2--84.5 Complete androgen blockade, followed by monotherapy202626.921.07.81.0--85.8 Other^b^1221.629.71.81.8--87.3Men diagnosed with M0 disease BIC monotherapy105618.44.31.00.2--83.3 Complete androgen blockade323356.41.01.00.1--84.5  BIC only within ± 2 months of LHRH agonist start19601.01.00.1--3.8  All other BIC and CAB use12734.73.00.2--84.5 Complete androgen blockade, followed by monotherapy135323.621.37.81.0--84.6  Other^b^861.530.112.01.9--87.3Men diagnosed with M1 disease BIC monotherapy16414.84.41.00.2--35.7 Complete androgen block45641.33.61.00.1--66.9  BIC only within ± 2 months of LHRH agonist start1601.01.00.1--2.9  All other BIC and CAB use2966.21.00.5--66.9 Complete androgen block, followed by monotherapy46542.118.316.61.0--83.9  Other^b^201.827.85--1.8--78.9*BIC* bicalutamide, *CAB* complete androgen blockade, *LHRH* luteinizing hormone-releasing hormone analog, *M0* patients without metastatic disease at diagnosis, *M1* patients with metastatic disease at diagnosis^a^Duration calculated in months from the first BIC claim to the last BIC claim plus the number of days' supply^b^Defined in Table [2](#Tab2){ref-type="table"}

Sensitivity Analysis {#Sec9}
--------------------

With respect to a sensitivity analysis, expanding the window between BIC prescription and initiation of LHRH agonist for CAB to a 4-month window, the proportion of patients using BIC monotherapy and CAB followed by monotherapy increased (19 and 32%, respectively), while the proportion of patients using BIC as part of CAB decreased to 47% (Supplemental Table 1). Among patients using BIC as part of CAB, a greater proportion (66%) used BIC within the potential testosterone flare prevention period. These patterns were also observed when the analyses were stratified by men diagnosed with and without metastases at diagnosis (49 and 34% used BIC as part of CAB, respectively).

Discussion {#Sec10}
==========

To our knowledge, this is the first study to determine the demographic and clinical characteristics of a cohort of elderly US prostate cancer patients using BIC and to compare various treatment patterns of BIC use alone, as part of CAB, or as part of CAB followed by monotherapy. Our study reported that greater than 44% of prostate cancer patients used BIC alone or as part of CAB followed by monotherapy, for which there is no FDA indication. Moreover, we found wide variation in the duration of BIC use, but the majority of utilization indicates relatively short durations of treatment in prostate cancer patients initially diagnosed with either M1 or M0 disease.

With low clinical benefit and weak clinical evidence strength in multiple prostate cancer settings, BIC has weak recommendation strength in several clinical guidelines \[[@CR28]--[@CR30]\]. A recent systematic review of clinical flare after LHRH agonist use identified a lack of historical data demonstrating disease progression during testosterone flare and hypothesized that anti-androgen use for flare prevention may be unnecessary \[[@CR7]\]. In the largest randomized controlled trial to date using BIC monotherapy at high doses for early-stage prostate cancer, there were indications of a delay in disease progression, but no statistically significant improvement in overall survival compared with standard-of-care therapy \[[@CR31]\]. Controlled clinical trial data to support BIC use in patients with castration-resistant prostate cancer are also sparse, with little clinical benefit reported when BIC was added to ongoing ADT \[[@CR32]--[@CR34]\]. Lastly, in a double-blind, placebo controlled, randomized clinical trial to examine the benefit of adding 150 mg of BIC to men undergoing radiation therapy with T2 and T3 disease observed improved overall survival, lower prostate cancer-specific mortality, and lower incidence of metastases \[[@CR35]\]. The use of claims data to determine non-US-approved 150-mg BIC use coupled with radiation treatment is difficult due to reliance on claim dates. However, in this analysis, 21% of patients received only BIC while also undergoing radiation treatment.

In the recent TERRAIN and STRIVE randomized controlled trials that included castration-resistant prostate cancer patients, only 21--31% of those treated with BIC (while on ADT) had a decline in their PSA of at least 50% \[[@CR2], [@CR36]\]. In light of the newer and more efficacious anti-androgens available, monotherapy BIC and the serial use of ADT followed by BIC monotherapy observed in this cohort should warrant future observational or controlled studies for anti-androgen efficacy in these treatment settings. This is important, as anti-androgen withdrawal syndrome may occur after discontinuation of BIC, causing a decline in PSA that may lead to androgen receptor overexpression and induce disease progression \[[@CR36]\]. In such cases, BIC can function as an androgen receptor partial agonist, which may induce disease progression \[[@CR37], [@CR38]\]. Enzalutamide, a potent second-generation oral androgen receptor inhibitor, was shown to have a statistically significant reduced risk of death as well as disease progression in two large randomized control trials evaluating treatment either before or after chemotherapy \[[@CR39], [@CR40]\]. Although a recent observational study of 47 metastatic castration-resistant prostate cancer patients treated with enzalutamide observed anti-androgen withdrawal syndrome in five patients (10.6%) after discontinuation of enzalutamide therapy \[[@CR41]\], in contrast to BIC, enzalutamide does not have agonist activity for the wild-type androgen receptor \[[@CR42], [@CR43]\]. Furthermore, enzalutamide impairs nuclear translocation of the androgen receptor and DNA binding that can lead to reduced expression of androgen-dependent genes \[[@CR42], [@CR44]\].

There are multiple limitations associated with this study. As the SEER registry only records cancer stage at diagnosis, the post-diagnosis metastatic status of this cohort during BIC use was unknown and cannot readily be determined from administrative claims data. Thus, patients could not be accurately characterized as to whether BIC was used only in patients with metastatic disease or non-metastatic disease. Due to SEER-Medicare limitations, we were not able to perform the study on younger men; in addition, patient selection biases (e.g., preservation of sexual function) that were not assessed may have led to variability in observations. Moreover, we cannot associate utilization with clinical intent of the prescribing physician. Further, the STRIVE \[[@CR36]\] and TERRAIN \[[@CR2]\] studies published in 2015 and 2016 were after the time period that data were available for this analysis. This study does not reflect clinician behavior following the publication of these trials. Additionally, no formal recommendations have been made as to the duration of CAB treatment. Clinical trials of CAB have shown advantages of 3- and 6-month treatment duration \[[@CR45]\]. A formalized recommendation for CAB treatment duration would guide both clinicians and researchers in their abilities to use and evaluate this therapy option.

Conclusions {#Sec11}
===========

Despite the absence of prospective randomized control trial during and before the study period, demonstrating an overall survival advantage with BIC and no FDA indication for BIC monotherapy, more than 44% of prostate cancer patients in this study used BIC alone or as part of CAB followed by monotherapy. Given the potential for adverse side effects after BIC treatment, and in light of other more efficacious second-generation anti-androgens currently available, future studies evaluating the risks, benefits, and outcomes associated with the BIC treatment patterns identified in this study are warranted.
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